Table 4.

Serious infections during randomized retreatment period. Data are number of patients (%).

Serious InfectionsRetreatment with Placebo (n = 155)Retreatment with Rituximab (n = 320)
Total serious infections3 (2)7 (2)
Pneumonia*12
Abdominal wall abscess10
Gastroenteritis01
Perirectal abscess01
Urosepsis01
Pyelonephritis10
Bursitis01
Acute respiratory distress syndrome*11
  • Infectious serious adverse events or non-SAE infections treated with intravenous antibiotics.

  • * Same patient, led to death.